NCT Research

News

vom 08.04.2016

Strong partners in oncology- Roche supervising board visits the NCT

The NCT, DKFZ and the University Hospital Heidelberg welcomed leading representatives of the F. Hoffmann-La Roche AG.
The NCT, DKFZ and the University Hospital Heidelberg welcomed leading representatives of the F. Hoffmann-La Roche AG.

“The partnership with Roche is tremendously helpful for us to faster implement new findings of molecular cancer research into projects, relevant for patients”, says Professor Dr. Christof von Kalle, Managing Director of the National Center for Tumor Diseases (NCT) Heidelberg, on the occasion of the visit of leading representatives of the F. Hoffmann-La Roche AG on February 11th 2016. “Our joint task is to treat cancer in a more targeted and better way.“ Lectures and guided tours from partners of the NCT, the German Cancer Research Center (DKFZ) and the University Hospital Heidelberg, offered the visitors of Roche the opportunity to convince themselves of the successful cooperation.

F. Hoffmann-La Roche AG, one of the largest manufactures of innovative cancer medications, closely cooperates with the NCT, the DKFZ and the University Hospital Heidelberg for many years now. The cooperation of personalized medicine in oncology between the DKFZ, the Heidelberg University Hospital and Roche was established in a cooperation agreement in 2012 and extended for another five years in 2015. The defined goal is to initiate new research projects already early on in the development of treatment approaches in order to continually enhance cancer therapy. New findings shall find their way to the patient in the fastest way possible. The necessary clinical trials for this purpose will be conducted at the NCT and the departments of the Heidelberg University Hospital.

“At Roche - and at the Network of Clinics and Science Heidelberg – we connect competencies in the areas of cancer therapy, diagnostics and digital health information to further advance personalized cancer treatment. Let us further develop and extend this approach together”, emphasizes Dr. Christoph Franz, President of the supervising board of the Roche Holding AG, the joint aim of the partners, to continue intensifying their cooperation.